GlassScriptPhysician profile
David M Mccaskill
NPI 1558353169
$26,536.27
in general payments reported to CMS, 2019-2025
26 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,024 · 2022: $2,279 · 2023: $4,083 · 2024: $5,695 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $8,200 · Food and Beverage: $8,091 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,800 · Travel and Lodging: $2,747 · Consulting Fee: $375 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $8,200.00 |
| Food and Beverage | $8,090.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,800.00 |
| Travel and Lodging | $2,747.31 |
| Consulting Fee | $375.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $12,165.02 | 2022-2025 | Optimizer, Optimizer |
| Pfizer INC. | $4,170.75 | 2021-2025 | |
| Abbott Laboratories | $3,202.42 | 2021-2025 | Cardiomems, Mitraclip |
| Cvrx, INC. | $1,760.68 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $998.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $643.29 | 2021-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $594.00 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $518.92 | 2022-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $373.09 | 2021-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $284.51 | 2021-2024 | Verquvo |
| Boston Scientific Corporation | $272.14 | 2022-2025 | General - Therapies, General - Ep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.81 | 2021-2024 | Jardiance, Ofev |
| Alnylam Pharmaceuticals INC. | $225.01 | 2022-2025 | Amvuttra |
| Medtronic, INC. | $193.12 | 2022-2024 | Corevalve Evolut R, Onyx Frontier |
| Novo Nordisk INC | $160.85 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $157.49 | 2022-2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $132.03 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $114.94 | 2022 | |
| Atricure, INC. | $104.69 | 2022 | |
| Biosense Webster, INC. | $68.38 | 2024 | Carto 3 |
| Sanofi-Aventis U.S. LLC | $50.31 | 2022-2024 | |
| Lexicon Pharmaceuticals, INC. | $45.13 | 2023-2024 | Inpefa |
| Angiodynamics, INC. | $24.20 | 2023 | Auryon Laser System 100-120 Vac |
| Scpharmaceuticals INC. | $24.18 | 2024 | |
| Siemens Medical Solutions USA, INC. | $14.23 | 2023 | Artis Icono Biplane |
| Argon Medical Devices, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mccaskill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.